CLINICAL TRIALS PROFILE FOR LEVOCARNITINE

All Clinical Trials for levocarnitine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000885 ↗	Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	Group A: To compare the time to confirmed virologic failure (2 consecutive plasma HIV-RNA concentrations of 500 copies/ml or more) between the treatment arms: abacavir (ABC) or placebo in combination with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). To evaluate the safety and tolerability of these treatment arms. [AS PER AMENDMENT 06/16/99: To compare the time to confirmed treatment failure, permanent discontinuation of treatment, or death between the treatment arms.] [AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable.] Group B: To compare the proportion of patients who achieve plasma HIV-1 RNA concentrations below 500 copies/ml, as assessed by the standard Roche Amplicor assay at Week 16, or to compare the absolute changes in plasma HIV-1 RNA concentrations at Week 16 across the treatment arms: ABC or approved nucleoside analogs and nelfinavir (NFV) or placebo in combination with efavirenz (EFV) and adefovir dipivoxil. To compare the safety and tolerability of these treatment arms. Group C: To monitor plasma HIV-1 RNA trajectory over time and determine the time to a confirmed plasma HIV-1 RNA concentration above 2,000 copies/ml on 2 consecutive determinations for patients treated with ZDV or stavudine (d4T) plus 3TC and IDV. Group D: To evaluate plasma HIV-1 RNA responses at Weeks 16 and 48. To evaluate the safety and tolerability of the treatment arms: ABC, EFV, adefovir dipivoxil, and NFV. This study explores new treatment options for ACTG 320 enrollees (and, if needed, a limited number of non-ACTG 320 volunteers) who have been receiving ZDV (or d4T) plus 3TC and IDV and are currently exhibiting a range of virologic responses. By dividing the study into the corresponding, nonsequential cohorts (Groups A, B, C, D), different approaches to evaluating virologic success, i.e., undetectable plasma HIV-1 RNA levels, and virologic failure, i.e., plasma HIV-1 RNA levels of 500 copies/ml or more [AS PER AMENDMENT 12/27/01: 200 copies/ml or more], are explored while maintaining long-term follow-up of ACTG 320 patients. [AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable. This study will examine the question of whether intensification of therapy can prolong the virologic benefit in individuals whose plasma HIV-1 RNA concentrations have been below the limits of assay detection on ZDV (or d4T) plus 3TC plus IDV.]
NCT00000892 ↗	A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16 weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm. While indinavir is currently the most commonly prescribed protease inhibitor, the optimal therapy for a person on an indinavir-containing regimen who experiences a rebound in viral load or never experiences a decrease in viral load below 500 copies per milliliter is unknown. Current clinical practice for such patients typically involves empiric use of a combination of other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir) and at least 1 other antiretroviral agent to which the patient has had little or no prior exposure. This may involve the use of 1 or more reverse transcriptase inhibitors (RTIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs). This study attempts to formally evaluate some of these options in indinavir-experienced patients.
NCT00000912 ↗	A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while on the treatment. This study evaluates the safety of these drug combinations, which include an experimental protease inhibitor (PI), amprenavir. Despite the success that many patients have had with PI treatment regimens, there is still a possibility that patients receiving PIs may continue to have high HIV blood levels. Because of this possibility, alternative drug combinations containing PIs are being studied. It appears that amprenavir, when taken with 3 or 4 other anti-HIV drugs, may be effective in patients with prior PI treatment experience.
NCT00001082 ↗	The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1996-12-01	To evaluate the safety and efficacy of adefovir dipivoxil in prolonging survival of patients with advanced HIV disease. In CMV prophylaxis substudy: To evaluate the efficacy of adefovir dipivoxil in preventing the development of CMV end-organ disease in patients with advanced HIV coinfected with CMV. The optimal treatment for HIV infection and the prevention of CMV disease has not been identified. Currently available antiretroviral therapies are hampered by both significant toxicities and the development of resistance. In addition, agents for preventing CMV disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased compliance secondary to toxicities. Moreover, discordant results have been reported regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2 and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able to decrease the incidence of opportunistic herpesvirus infections and prolong survival in patients with advanced HIV infection.
NCT00001087 ↗	The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	Steps I and II: The purpose of this study is the following: To look at how many patients achieve undetectable HIV blood levels at Week 16. To look at the absolute change in HIV blood levels from the beginning of the study to Week 16. To look at the safety and tolerability of nelfinavir (NFV) and efavirenz (EFV) when used in combination or separately in regimens containing reverse transcriptase inhibitors (RTIs). For the 2 extension studies (Weeks 49 to 144): To look at the proportion of patients whose long-term viral load remains undetectable at Week 96. To look at the time from the beginning of the study to treatment failure, with patients evaluated through Week 144. Step III: To look at the proportion of patients whose HIV blood levels are undetectable 16 weeks after starting the salvage study treatment. To assess safety, toxicity, and tolerance of salvage study drug treatment. (This study has been changed by adding new objectives.) Achieving viral suppression has been widely endorsed as the primary goal of HIV therapy. However, there are few established guidelines for devising combinations of different classes of drugs which will enhance the potential for achieving viral suppression, reducing the risk of toxicity, and preserving therapeutic options for future use. This study includes 2 anti-HIV drugs, NFV (a protease inhibitor [PI]) and EFV (a nonnucleoside reverse transcriptase inhibitor [NNRTI]), for use either alone or in combination with RTI therapy for the purpose of limiting HIV replication. Patients with treatment failure at Week 16 choose 1 of the following 3 alternative salvage therapies: 2-drug PI regimen (saquinavir and ritonavir) plus adefovir dipivoxil and L-carnitine; EFV or NFV (if not already given) plus 2 new approved anti-HIV drugs outside the study; or the best available treatment outside the study. The new RTI, adefovir dipivoxil, is added to the 2-drug PI regimen to achieve suppression of viral replication and thereby delay disease progression. (This rationale reflects a change in the treatment given to patients with treatment failure at Week 16.)
NCT00002184 ↗	A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibit	Completed	Gilead Sciences	Phase 2	1969-12-31	To evaluate the safety and tolerance of the combination of adefovir dipivoxil at two comparative doses and nelfinavir plus saquinavir SGC administered orally (Group 1) vs. the combination of adefovir dipivoxil and nelfinavir plus either zidovudine, lamivudine, or stavudine (Group 2) vs. the combination of adefovir dipivoxil and saquinavir SGC plus either zidovudine, lamivudine, or stavudine (Group 3) in HIV-infected patients with prior nucleoside reverse transcriptase inhibitor therapy but no prior exposure to protease inhibitors who have CD4 cell counts >= 100 cells/mm3 and an HIV-1 RNA baseline copy number >= 5000 copies/ml. To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (
NCT00002219 ↗	Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children	Unknown status	Gilead Sciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give adefovir (a new anti-HIV drug) plus nelfinavir to HIV-infected children who are already receiving other anti-HIV medications.

Clinical Trial Conditions for levocarnitine

Condition Name

Condition Name for levocarnitine
Intervention	Trials
HIV Infections	11
Carnitine Deficiency	2
Acute Lymphoblastic Leukemia	2
Patient Compliance	2

Condition MeSH

Condition MeSH for levocarnitine
Intervention	Trials
HIV Infections	11
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Leukemia, Lymphoid	3
Leukemia	3

Clinical Trial Locations for levocarnitine

Trials by Country

Trials by Country for levocarnitine
Location	Trials
United States	135
Puerto Rico	5
Egypt	2
Bangladesh	2
Mexico	1

Trials by US State

Trials by US State for levocarnitine
Location	Trials
New York	12
California	10
Maryland	8
Texas	8
Massachusetts	7

Clinical Trial Progress for levocarnitine

Clinical Trial Phase

Clinical Trial Phase for levocarnitine
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	2
Phase 3	4

Clinical Trial Status

Clinical Trial Status for levocarnitine
Clinical Trial Phase	Trials
Completed	11
Unknown status	6
Not yet recruiting	4

Clinical Trial Sponsors for levocarnitine

Sponsor Name

Sponsor Name for levocarnitine
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	5
Gilead Sciences	4
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	2

Sponsor Type

Sponsor Type for levocarnitine
Sponsor	Trials
Other	17
NIH	7
Industry	6

Levocarnitine: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 25, 2026

What is levocarnitine’s clinical-trial footprint today?

Levocarnitine (L-carnitine) is a long-established metabolite used across multiple indications where carnitine deficiency or fatty-acid oxidation defects are implicated. Clinical development continues largely in label-expansion, special populations, and formulation or regimen optimization rather than first-in-class breakthroughs.

Clinical development pattern (high level)

Across recent years, levocarnitine trials most commonly focus on:

• Primary or secondary carnitine deficiency syndromes
• Fatty-acid oxidation disorders and related metabolic conditions
• Supportive or adjunctive use in specific disease settings where carnitine metabolism is impaired
• Pediatric and rare-disease cohorts (including regimen and dosing studies)
• Formulation comparisons (oral solution, tablets, IV preparations) and pharmacokinetic (PK) endpoints

Trial update status

Public registries show ongoing activity, but the current pipeline is dominated by:

• Small-to-mid size studies typical of rare metabolic indications
• Studies aimed at clinical endpoints that map to metabolic control, symptom burden, or biochemical response
• Safety and tolerability confirmation across age groups

Market implication: the trial mix is consistent with a mature molecule where incremental clinical differentiation is the main pathway to value capture, not platform-level innovation.

---

Which indications still drive clinical and commercial relevance?

Levocarnitine’s commercial pull remains strongest in areas where there is a clear mechanistic deficit and a stable prescriber base.

Core clinical-anchoring indications

1. Primary carnitine deficiency (PCD)
   • Chronic therapy; long-term use creates durable demand
2. Secondary carnitine deficiency
   • Drug-induced or disease-associated depletion; demand depends on comorbidity patterns and local formularies
3. Inborn errors of metabolism affecting fatty-acid oxidation
   • Use aligns with metabolic management protocols and specialist treatment pathways

Adjunctive and supportive use

Levocarnitine is also used in off-protocol or protocol-linked settings depending on geography and guideline adoption (for example, where metabolic support is part of standard care). These uses tend to be more variable by region, reimbursement, and clinical practice norms.

---

What does the market look like for levocarnitine?

Levocarnitine is an established, widely sourced molecule. Market dynamics are shaped by:

• Generics and multiple manufacturers in many geographies
• Formulation breadth (oral and IV)
• Reimbursement and guideline-driven prescribing in deficiency states
• Tender and hospital contracting for IV use

Demand drivers

Durable demand is produced by chronic treatment of deficiency states, particularly in PCD. Secondary deficiency demand is tied to prevalence of underlying causes and prescribing behavior for at-risk patients.

Supply and pricing

Levocarnitine pricing typically reflects:

• Competitive generic supply for oral formulations
• Hospital procurement dynamics for IV preparations
• Variability by country due to regulatory approvals and the availability of locally marketed products

Investment implication: returns depend more on distribution scale, tender competitiveness, and stable access than on pricing power.

---

How is the competitive landscape structured?

The levocarnitine market is fragmented among multiple generic manufacturers plus brand-originated products in certain regions.

Competitive clusters

• Oral levocarnitine products for chronic deficiency maintenance
• IV levocarnitine for acute metabolic decompensation or inpatient protocols
• Special pediatric formulations (drops/solutions) where dosing accuracy is critical

What differentiates winners in practice

• Reliability of supply for hospital formularies
• Regulatory continuity (batch approvals, ongoing compliance)
• Contracting performance for tenders
• Formulation usability (dosing device, stability, shelf-life)

---

What revenue and volume forecast is most likely over the next cycle?

A defensible projection for a mature, generics-heavy molecule is based on:

• Expected growth in treated patients for deficiency indications
• Population growth and improved diagnosis
• Sustained market penetration of established formulations
• Modest share shifts driven by procurement and product availability

Projection framework (base case)

• Volume growth: modest, anchored to treated prevalence and continuity of therapy
• Value growth: typically slower than volume due to generic price competition
• Segment mix: gradual shift toward forms that minimize administration burden (where reimbursement supports it)

Scenario logic

• Upside: faster diagnosis uptake for PCD, broader adoption of specialist protocols, and improved access in underpenetrated regions
• Downside: pricing pressure from increased generic supply, tender price resets, and substitution away from certain formulations

---

What clinical and regulatory milestones matter for near-term catalysts?

For levocarnitine, the most credible catalysts tend to be:

• Completion and publication of new regimen/PK and safety results in pediatric or rare-disease cohorts
• Regulatory updates that expand label language in specific deficiency contexts
• Commercial catalysts tied to formulation approvals, access expansions, or hospital tender wins

Why trial outcomes move the market

Because the molecule already has established clinical use, evidence tends to matter most for:

• Confirming dosing and safety in subpopulations
• Reinforcing guideline alignment
• Supporting specific label language that strengthens reimbursement eligibility

---

What’s the investment case: where value is created?

With a mature molecule, value creation is tied to operational execution rather than breakthrough IP.

High-probability value levers

• Distribution and contracting in hospital channels for IV indications
• Pediatric formulation dominance through dosing convenience and stability
• Geographic expansion where regulatory approvals still lag
• Supply reliability for tender-dependent buyers

Low-probability value levers

• Large pricing step-ups without exclusivity
• Broad claims that materially expand patient pools beyond deficiency frameworks

---

Key Takeaways

• Levocarnitine’s clinical pipeline remains active but is dominated by incremental studies (PK, dosing, special populations) rather than new mechanisms.
• Market demand is anchored in chronic deficiency and metabolic disorders, with additional variability from secondary deficiency and supportive use.
• The market is generics-heavy; value growth depends more on volume capture, contracting strength, and formulation access than on pricing power.
• Near-term catalysts most often come from study publications that support label precision, reimbursement eligibility, and clinician confidence in dosing for specific populations.

---

FAQs

1. Is levocarnitine still being studied in new clinical populations?
   Yes. Trial activity centers on special populations, including pediatric cohorts and metabolic-risk groups, with emphasis on dosing, safety, and metabolic response endpoints.

2. What indication most stabilizes levocarnitine demand?
   Primary carnitine deficiency, where long-term therapy drives sustained utilization.

3. How does IV vs oral formulation affect market dynamics?
   IV demand is more tied to hospital protocols and tender procurement, while oral demand is driven by chronic outpatient management and dosing usability.

4. Where do competitive gains typically come from in levocarnitine?
   Supply reliability, hospital contracting performance, and pediatric-friendly formulation availability are the primary levers.

5. Do clinical trial results typically change pricing for levocarnitine?
   In a generics-heavy market, trial-driven label refinement can improve access and reimbursement eligibility, but it rarely creates pricing power without exclusivity.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency (EMA). Levocarnitine related information and assessments via EMA product/EPAR pages. https://www.ema.europa.eu/
[3] U.S. Food and Drug Administration (FDA). Drug labels and product information for levocarnitine-containing medicines. https://www.accessdata.fda.gov/